VIELIGHT, Inc.

Key Partnerships

Apollo Health

Strategic partnership to integrate Vielight's Neuro Gamma device into the Bredesen Protocol for cognitive health, focusing on home-use brain photobiomodulation (PBM) technology.

Academic/Medical Institutions

Harvard Medical School: Collaborated on a landmark 2015 dementia trial demonstrating cognitive improvements.

University of California: Conducted fMRI studies validating Vielight's Neuro Gamma efficacy.

U.S. Department of Veterans Affairs (VA): Research collaborations on PBM applications.

Research Collaborators

Vielight works with multiple institutions on clinical trials for Alzheimer’s, traumatic brain injury, PTSD, and ADHD.

Funding and Investors

No corporate investors are listed in the provided materials.

Vielight mentions grants and research funding (e.g., FDA/Health Canada-approved trials post-2015), but details about equity investors or venture capital firms are absent.

Revenue appears driven by direct sales (e.g., Neuro Gamma priced at $1,799) and partnership programs (reseller/affiliate models).

Business Model

Reseller/Affiliate Programs: Partnerships with health practitioners and businesses to distribute devices.

Research Collaborations: Focus on clinical validation with academic institutions